| Autor: |
Peter K. Selleh, Enoch O. Anto, Wina I. O. Boadu, Benedict Sackey, Lilian A. Boateng, Charles Nkansah, Frederick Nsafoah, Abdul R. Saasi, Selina Mintaah, Yaw A. Wiafe, Charles Derigubah, Emmanuel E. Korsah, Joseph Frimpong, Ezekiel Ansah, Valentine C. K. T. Tamakloe, Patrick Adu, Joseph Boachie, Otchere Addai‐Mensah |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Health Science Reports, Vol 6, Iss 6, Pp n/a-n/a (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2398-8835 |
| DOI: |
10.1002/hsr2.1297 |
| Popis: |
Abstract Background and Aims Type 2 diabetes mellitus (T2DM) individuals are at a higher risk of developing diabetes complications, with approximately 80% complication‐related mortality. The increased morbidity and mortality among T2DM patients are partly due to dysregulated hemostasis. This study determined the quality of glycemic control in T2DM and its association with markers of coagulation and inhibitors of fibrinolysis. Methods This case–control study recruited 90 participants involving: 30 T2DM patients with good glycemic control, 30 with poor glycemic control, and 30 nondiabetic subjects as controls at a Municipal Hospital in Ghana. Fasting blood glucose, glycated hemoglobin, activated partial thromboplastin time (APTT), prothrombin time (PT), calculated international normalized ratio (INR), and full blood count (FBC) were determined for each respondent. Plasma levels of plasminogen activator inhibitor‐1 (PAI‐1) and thrombin activatable fibrinolysis inhibitor (TAFI) were determined using the solid‐phase sandwich enzyme‐linked immunosorbent assay method. Data were analyzed using R language software. Results Plasma PAI‐1 antigen levels were significantly higher in the participants with poor glycemic control as compared to participants with good glycemic control (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text